Combined GSTM1 and GSTT1 null genotypes are associated with a lower risk of papillary thyroid cancer

Journal of Endocrinological Investigation

Volumn 31, Issue 6, 2008, Pages 542-545

  Lemos, M C ^a,b,c   Coutinho, E ^b   Gomes, L ^c   Carrilho, F ^c   Rodrigues, F ^c,d   Regateiro, F J ^b   Carvalheiro, M ^c  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

Author keywords

Genetic polymorphisms; GSTM1; GSTT1; Thyroid cancer

Indexed keywords

GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NULL ALLELE; POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA;

EID: 48449089834     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346405     Document Type: Article

References (26)

1. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006, 25: 1639-48.
2. Seidegård J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A 1988, 85: 7293-7.
3. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione S-transferase theta (GSTT1): cDNA, cloning and the characterization of a genetic polymorphism. Biochem J 1994, 300: 271-6.
4. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001, 10: 1239-48.
5. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997, 6: 733-43.
6. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000, 463: 247-83.
7. Parl FF. Glutathione S-transferase genotypes and cancer risk. Cancer Lett 2005, 221: 123-9.
8. Morari EC, Leite JL, Granja F, da Assumpção LV, Ward LS. The null genotype of glutathione s-transferase M1 and T1 locus increases the risk for thyroid cancer. Cancer Epidemiol Biomarkers Prev 2002, 11: 1485-8.
9. Hernández A, Céspedes W, Xamena N, et al. Glutathione S-transferase polymorphisms in thyroid cancer patients. Cancer Lett 2003, 190: 37-44.
10. Gaspar J, Rodrigues S, Gil OM, et al. Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk. Cancer Genet Cytogenet 2004, 151: 60-7.
11. Stankov K, Landi S, Gioia-Patricola L, et al. GSTT1 and M1 polymorphisms in Hürthle thyroid cancer patients. Cancer Lett 2006, 240: 76-82.
12. Ho T, Zhao C, Zheng R, Liu Z, Wei Q, Sturgis EM. Glutathione S-transferase polymorphisms and risk of differentiated thyroid carcinomas: a case-control analysis. Arch Otolaryngol Head Neck Surg 2006, 132: 756-61.
13. Sobin L, Wittekind C. TNM classification of malignant tumours. 5th ed, New York: Wiley-Liss, 1997.
14. Fleming I, Cooper J, Hensen D, et al. AJCC: Cancer staging manual. 5th ed, Philadelphia: Lippincott-Raven, 1997.
15. Muiras ML, Verasdonck P, Cottet F, Schachter F. Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci. Hum Genet 1998, 102: 526-32.
16. Lemos MC, Regateiro FJ. N-acetyltransferase genotypes in the Portuguese population. Pharmacogenetics 1998, 8: 561-4.
17. Lemos MC, Cabrita FJ, Silva HA, et al. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999, 20: 1225-9.
18. Sobrinho-Simões M, Preto A, Rocha AS, et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 2005, 447: 787-93.
19. Chang HY, Lin JD, Chou SC, Chao TC, Hsueh C. Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas. Jpn J Clin Oncol 2006, 36: 688-93.
20. Hagag P, Hod N, Kummer E, Cohenpour M, Horne T, Weiss M. Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up. Cancer J 2006, 12: 275-82.
21. van Bladeren PJ. Glutathione conjugation as a bioactivation reaction. Chem Biol Interact 2000, 129: 61-76.
22. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6: 292-306.
23. Hard GC. Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Environ Health Perspect 1998, 106: 427-36.
24. Kirsch-Volders M, Mateuca RA, Roelants M, et al. The effects of GSTM1 and GSTT1 polymorphisms on micronucleus frequencies in human lymphocytes in vivo. Cancer Epidemiol Biomarkers Prev 2006, 15: 1038-42.
25. Bufalo NE, Leite JL, Guilhen AC, et al. Smoking and susceptibility to thyroid cancer: an inverse association with CYP1A1 allelic variants. Endocr Relat Cancer 2006, 13: 1185-93.
26. Lemos MC, Carrilho F, Rodrigues F, et al. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer. Clin Endocrinol (Oxf) 2007, 67: 180-3.